The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 1584)
LRRK2 Biology Consortium, 2018
Parkinson's disease (PD) affects nearly any body system, as evidenced by the diversity of its symptoms. While its non-motor symptoms, such as olfactory dysfunction, rapid eye movement sleep behavior disorder (RBD) and gastrointestinal (GI) abnormalities, do not define the disease, they have a large impact on those living with it. In this project, we will use a pre-clinical model o...
Researchers: R. Jeremy Nichols, PhD
Research Grant, 2018
There is a pressing need for Parkinson's disease (PD) biomarkers -- objective measures of disease -- that will enable early and accurate diagnosis and allow to track disease progression and therapeutic improvement. We have developed a new mathematical method to characterize PD-related brain networks. This method is based on a mathematical analysis of data collected via resting sta...
Computational Science 2017, 2018
Clinical research as well as wearable devices and phone apps used by people with Parkinson's disease (PD) generate large volumes of data, such as genetic and imaging data and data on motor symptoms. The extreme complexity and volume of this data call for new, efficient computer analysis methods.
Neural-network-based learning is a programming approach inspired by the rema...
Target Validation, 2017
Toll-like Receptor Inhibition to Block Alpha-synuclein-induced Pro-inflammatory Signaling and Cytokine Release
Synucleinopathies, including Parkinson's disease (PD), are a family of central nervous system (CNS) degenerative disorders characterized by alpha-synuclein protein-containing aggregates. Toll-like receptors (TLRs), which includes TLR2, play a critical role in the immune system's response to foreign pathogens that can trigger adverse inflammatory signaling. Recently, alpha-synuclein...
Researchers: Martin B. Gill, PhD
Improved Biomarkers & Clinical Outcome Measures, 2017
Dopamine Buffering Capacity Measured by phMRI as a Novel Biomarker of Disease Progression in Parkinson's Disease
This project will test a new idea for measuring the severity of Parkinson's disease (PD). The brain acts as if it can store each dose of levodopa (L DOPA) for a short period of time and lets it "leak" into the brain when needed. This levodopa reservoir appears to get "leakier" as PD progresses, contributing to a gradually briefer benefit from each dose of the drug. The new idea we...
Researchers: Kevin J. Black, MD